TY - JOUR
T1 - Inhibition of NADPH oxidase by glucosylceramide confers chemoresistance
AU - Barth, Brian M.
AU - Gustafson, Sally J.
AU - Young, Megan M.
AU - Fox, Todd E.
AU - Shanmugavelandy, Sriram S.
AU - Kaiser, James M.
AU - Cabot, Myles C.
AU - Kester, Mark
AU - Kuhn, Thomas B.
N1 - Funding Information:
We would like to thank Keystone Nano, Inc., (State College, PA) and in particular Amy Knupp and Dr. Mylisa Parette, for the use of and assistance with, the Malvern Zetasizer Nano instrument. We graciously thank Dr. Yixing Jiang, of the Milton S. Hershey Penn State Medical Center, for kindly providing gemcitabine. Discussions with Dr. Marvin Schulte, Dr. Barbara Taylor and Dr. Kristin O’Brien, of the University of Alaska-Fairbanks, were helpful during the preparation of this manuscript. This research was funded in part by USDA grant 2005-34495-16519 (T.B.K.), NIH grant U54 NS41069 (T.B.K.) and NIGMS grant GM77391 (M.C.C.). Additional financial support was made possible by the College of Natural Sciences and Mathematics, University of Alaska-Fairbanks.
PY - 2010/12/1
Y1 - 2010/12/1
N2 - The bioactive sphingolipid ceramide induces oxidative stress by disrupting mitochondrial function and stimulating NADPH oxidase (NOX) activity, both implicated in cell death mechanisms. Many anticancer chemotherapeutics (anthracyclines, Vinca alkaloids, paclitaxel and fenretinide), as well as physiological stimuli such as tumor necrosis factor α (TNFα), stimulate ceramide accumulation and increase oxidative stress in malignant cells. Consequently, ceramide metabolism in malignant cells and, in particular the upregulation of glucosylceramide synthase (GCS), has gained considerable interest in contributing to chemoresistance. We hypothesized that increases in GCS activity and thus glucosylceramide, the product of GCS activity, represents an important resistance mechanism in glioblastoma. In our study, we determined that increased GCS activity effectively blocked reactive oxygen species formation by NOX. We further showed, in both glioblastoma and neuroblastoma cells that glucosylceramide directly interfered with NOX assembly, hence delineating a direct resistance mechanism. Collectively, our findings indicated that pharmacological or molecular targeting of GCS, using non-toxic nanoliposome delivery systems, successfully augmented NOX activity, and improved the efficacy of known chemotherapeutic agents.
AB - The bioactive sphingolipid ceramide induces oxidative stress by disrupting mitochondrial function and stimulating NADPH oxidase (NOX) activity, both implicated in cell death mechanisms. Many anticancer chemotherapeutics (anthracyclines, Vinca alkaloids, paclitaxel and fenretinide), as well as physiological stimuli such as tumor necrosis factor α (TNFα), stimulate ceramide accumulation and increase oxidative stress in malignant cells. Consequently, ceramide metabolism in malignant cells and, in particular the upregulation of glucosylceramide synthase (GCS), has gained considerable interest in contributing to chemoresistance. We hypothesized that increases in GCS activity and thus glucosylceramide, the product of GCS activity, represents an important resistance mechanism in glioblastoma. In our study, we determined that increased GCS activity effectively blocked reactive oxygen species formation by NOX. We further showed, in both glioblastoma and neuroblastoma cells that glucosylceramide directly interfered with NOX assembly, hence delineating a direct resistance mechanism. Collectively, our findings indicated that pharmacological or molecular targeting of GCS, using non-toxic nanoliposome delivery systems, successfully augmented NOX activity, and improved the efficacy of known chemotherapeutic agents.
UR - http://www.scopus.com/inward/record.url?scp=78649815908&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649815908&partnerID=8YFLogxK
U2 - 10.4161/cbt.10.11.13438
DO - 10.4161/cbt.10.11.13438
M3 - Article
C2 - 20935456
AN - SCOPUS:78649815908
SN - 1538-4047
VL - 10
SP - 1126
EP - 1136
JO - Cancer Biology and Therapy
JF - Cancer Biology and Therapy
IS - 11
ER -